Beyond Clinical Diagnostics
Figure 1. Loading results for analysis. Aptamers were first discovered in 1989 by Craig Tuerk and Larry Gold. The classic definition of an aptamer is a single-stranded oligonucleotide (RNA or DNA) that has the capacity to mimic an antibody in terms of binding to specific analytes. Many have predicted that this discovery represented a technology with the potential to rival the antibody revolution in molecular diagnostic testing. Years have passed, and while many aptamers have been...
The Clinical Lab Expo will feature new science and technology in every area of clinical diagnostics, automation, information systems, point of care, OEM, and biotech. Roughly 750 organizations will occupy about 2000 booths. According to Clinical Lab Expo's Website, "You will see more products in every clinical lab discipline than at any other show." Find What You Need The Clinical Lab Expo will have special sections for special products. Visit the special sections for point-of-...
Nonclinical diagnostic applications are typically more loosely regulated than their clinical counterparts, which is attractive to manufacturers. However, working effectively in nonclinical markets requires that manufacturers know what their nonclinical clients are seeking, what technology is required, and whether and how the final product is going to be used long-term. To learn more about the benefits and challenges of working in nonclinical diagnostics, IVD Technology editor Richard Park spoke...
The markets for molecular applied testing provide ample opportunity for growth. While human identification and forensics are established molecular marketplaces, the food- and animal-testing markets are now seeing molecular technologies gaining ground over traditional immunological tests. Across all segments of applied testing, customers are asking for the same thing: highly reliable, complete workflow solutions that produce results of the highest quality. To learn more about the current trends...
    The markets for molecular applied testing provide ample opportunity for growth. While human identification and forensics are established molecular marketplaces, the food- and animal-testing markets are now seeing molecular technologies gaining ground over traditional immunological tests. Across all segments of applied testing, customers are asking for the same thing: highly reliable, complete workflow solutions that produce results of the highest quality. To learn more about...
In vitro diagnostics is, by many accounts, an underrated, undervalued industry. While pharmaceutical and therapeutic medical-device innovations tend to garner most of the mainstream media’s attention, the fact remains that 60 to 70% of medical decisions are influenced by some type of diagnostic testing, yet diagnostics accounts for only a tiny fraction of overall healthcare spending.  Some of the major developments within this very important industry during the past 15 years include...
  For diagnostics manufacturers, entering into a contract with the military can be very lucrative and worthwhile; however, it is not for the faint of heart. From initial discussions to production of the final product, the process is very involved and can take years. To learn more about what a diagnostic company can expect when forging a relationship with the military or with local first-responder teams, IVD Technology editor Richard Park spoke with Matt Scullion, business development...
A report by Kalorama Information (New York), “The Worldwide Market for In Vitro Diagnostic Tests,” concluded that the future for immunoassays is a mixed bag. In the clinical laboratory, mature assays will show moderate growth while emerging assays will fuel most of the growth in this IVD segment. However, all immunoassays will have to pass the test of medical research to demonstrate their contributions to improving patient outcomes. For example, increased knowledge of disease...
Several conferences held last summer provided a basis for the notion that a relative gold rush of companion diagnostics in oncology is nearing reality. However, cancer biomarkers also present unique complexities for the lab industry, regulators, and physicians. The American Society for Clinical Oncology (ASCO) focused its 2009 meeting on the idea that a personalized medicine approach must become the standard for effective clinical oncology. Three years ago, Her-2/neu stood...
    In Person: Online Expanded Version         Rocky Ganske is president and CEO of Axela Inc., a life sciences company based in Toronto. He has more than 25 years of experience in the medical diagnostics and life sciences fields. He can be reached at r.ganske@axela.com. Manufacturers of human IVD technologies have been contributing their skills and knowledge more and more to the nonclinical and agricultural diagnostic markets. Turning their attention...